Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib versus watch-and-wait in early-stage high-risk CLL
2019-001804-39Phase 3Active
- Sponsor
- Fundación PETHEMA
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Acalabrutinib with Clinical observation (2 arms). Primary endpoint: Event-free survival. Started Jul 2019; status: active.
02
Drugs
acalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2019-001804-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001804-39.